Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.01835
European Journal of Endocrinology, Vol 152, Issue 1, 103-112
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haugaard, S. B
Right arrow Articles by Madsbad, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haugaard, S. B
Right arrow Articles by Madsbad, S.

CLINICAL STUDY

Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic ß-cells

Steen B Haugaard1,2,3, Ove Andersen1,3, Flemming Dela5, Jens Juul Holst6, Heidi Storgaard7, Mogens Fenger4, Johan Iversen1 and Sten Madsbad2

1 Department of Infectious Diseases, 2 Department of Internal Medicine and Endocrinology, 3 Clinical Research Unit and 4 Department of Clinical Biochemistry, Hvidovre University Hospital, Copenhagen, Denmark, 5 Copenhagen Muscle Research Centre/Department of Medical Physiology and 6 Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark and 7 Steno Diabetes Centre, Gentofte, University of Copenhagen, Copenhagen, Denmark

(Correspondence should be addressed to S B Haugaard, Clinical Research Unit 136, Hvidovre University Hospital, DK 2650 Hvidovre, Copenhagen, Denmark; Email: sbhau{at}dadlnet.dk)

Objectives: Lipodystrophy and insulin resistance are prevalent among human immunodeficiency virus (HIV)-infected patients on combined antiretroviral therapy (HAART). Aiming to provide a detailed description of the metabolic adverse effects of HIV-lipodystrophy, we investigated several aspects of glucose metabolism, lipid metabolism and ß-cell function in lipodystrophic HIV-infected patients.

Methods: [3-3H]glucose was applied during euglycaemic hyperinsulinaemic clamps in association with indirect calorimetry in 43 normoglycaemic HIV-infected patients (18 lipodystrophic patients on HAART (LIPO), 18 patients without lipodystrophy on HAART (NONLIPO) and seven patients who were naïve to antiretroviral therapy (NAÏVE) respectively). ß-cell function was evaluated by an intravenous glucose tolerance test.

Results: Compared with NONLIPO and NAÏVE separately, LIPO displayed markedly reduced ratio of limb to trunk fat (RLF; >34%, P < 0.001), hepatic insulin sensitivity (>40%, P < 0.03), incremental glucose disposal (>50%, P < 0.001) and incremental exogenous glucose storage (>50%, P < 0.05). Furthermore, LIPO displayed reduced incremental glucose oxidation (P < 0.01), increased clamp free fatty acids (P < 0.05) and attenuated insulin-mediated suppression of lipid oxidation (P < 0.05) compared with NONLIPO. In combined study groups, RLF correlated with hepatic insulin sensitivity (r = 0.69), incremental glucose disposal (r = 0.71) and incremental exogenous glucose storage (r = 0.40), all P < 0.01. Disposition index (i.e. first-phase insulin response to intravenous glucose multiplied by incremental glucose disposal) was reduced by 46% (P = 0.05) in LIPO compared with the combined groups of NONLIPO and NAÏVE, indicating an impaired adaptation of ß-cell function to insulin resistance in LIPO.

Conclusion: Our data suggest that normoglycaemic lipodystrophic HIV-infected patients display impaired glucose and lipid metabolism in multiple pathways involving liver, muscle tissue and ß-cell function.




This article has been cited by other articles:


Home page
Int J STD AIDSHome page
R. Manfredi and L. Calza
HIV infection and the pancreas: risk factors and potential management guidelines
Int J STD AIDS, February 1, 2008; 19(2): 99 - 105.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
B. Lindegaard, C. Frosig, A. M. W. Petersen, P. Plomgaard, S. Ditlevsen, B. Mittendorfer, G. Van Hall, J. F.P. Wojtaszewski, and B. K. Pedersen
Inhibition of Lipolysis Stimulates Peripheral Glucose Uptake but Has No Effect on Endogenous Glucose Production in HIV Lipodystrophy
Diabetes, August 1, 2007; 56(8): 2070 - 2077.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
J. B Albu, S. Kenya, Q. He, M. Wainwright, E. S Berk, S. Heshka, D. P Kotler, and E. S Engelson
Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women
Am. J. Clinical Nutrition, July 1, 2007; 86(1): 100 - 106.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. B. Haugaard, O. Andersen, S. Madsbad, C. Frosig, J. Iversen, J. O. Nielsen, and J. F.P. Wojtaszewski
Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy
Diabetes, December 1, 2005; 54(12): 3474 - 3483.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.